Glucagon-like peptide 1 receptor agonists and renal outcomes in kidney transplant recipients with diabetes mellitus

🎖️ Top 10% JournalFeb 17, 2025Diabetes & metabolism

Glucagon-like peptide 1 drugs and kidney health after transplant in people with diabetes

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

The use of GLP1-RAs is associated with 68 events per 1000-patient years in diabetic kidney transplant recipients compared to 114 events in non-users.

GLP1-RAs may lower the incidence of composite renal outcomes, including graft rejection and all-cause mortality.
Users of GLP1-RAs demonstrated improved glycemic control and lipid profiles.
There was a decrease in body mass index among GLP1-RA users.
The treatment did not lead to an increase in genitourinary infections or biliopancreatic adverse events.
Further prospective data is needed to confirm these findings in diabetic kidney transplant recipients.

AI simplified

AIMS: Glucagon-like peptide-1 receptor agonists (GLP1-RAs) show reno-protective effects in type 2 diabetes. Limited data is available on their use in post-transplant diabetes mellitus. We aimed to explore the effect of GLP1-RAs on renal outcomes in diabetic kidney transplant recipients (KTR).

METHODS: We conducted a cohort retrospective study on adult KTR with diabetes mellitus. KTR treated with GLP1-RAs were matched with non-users. The primary outcome was the first occurrence of graft rejection, start of dialysis, re-transplantation or all-cause mortality. Other outcomes included a composite of the first occurrence of a genitourinary infection or all-cause mortality, and all-cause mortality. Metabolic effects of GLP1-RA treatment and risk for biliopancreatic adverse events were also explored.

RESULTS: We included 272 patients (69 % males, average age 58.3 ± 11.0 years) with a 3.1-year median follow-up. The use of GLP1-RAs lowered the incidence of the composite renal outcome after adjustment for independent risk factors (114 versus 68 events per 1000-patient years in controls versus GLP1-RA users, HR 0.489, 95 % CI 0.271-0.883). GLP-RA users had improved glycemic control, lipid profile and a decrease in body mass index. The treatment was safe without increased genitourinary infections or biliopancreatic events.

CONCLUSION: The use of GLP1-RAs decreased the risk of a composite outcome of renal dysfunction and mortality, improved metabolic control and showed safety of use in a large cohort of diabetic KTR, suggesting reno-protective effects in this high-risk population. Prospective data is further needed in KTR who are excluded from large RCTs.

Full Text

Full text is available at the source.

View full text (XML) ↗View full text ↗

Abstract

Full Text

Related papers